Concepedia

Author

Sharat Singh

Prometheus Biosciences (United States)ORCID

Also Known As

Croner, Lisa, Hamor, C, S Singh, S. Robindro Singh, S. SINGH, S. Singh, S.Robindro Singh, SHARAT SINGH, Sharat Singh, Singh, S.

241

Publications

6K

Citations

36

H-Index

86

Concepts

All Affiliations

Prometheus Biosciences (United States)Indian Institute of Science BangaloreKU LeuvenPrometheus (United States)University of Miami
SS

About

Sharat Singh is an author at Prometheus Biosciences (United States) specializing in medicine, engineering, and chemistry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

19

1.8K

2

Engineering

10

11

785

3

Natural Sciences

6

6

202

4

Arts

1

1

23

5

Health Sciences

1

1

18

Sharat Singh

×

56

Publications

5.7K

Citations

35

H-Index

YearCitations

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Violeta Serra, Maurizio Scaltriti, Ludmila Prudkin,

Oncogene

2011

530

An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer

Belén Rubio‐Viqueira, Antonio Jimeno, George Cusatis,

Clinical Cancer Research

2006

411

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer

Moshe Elkabets, Sadhna Vora, Dejan Juric,

Science Translational Medicine

2013

344

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

Niels Vande Casteele, Ann Gils, Sharat Singh,

The American Journal of Gastroenterology

2013

342

Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence.

Edwin F. Ullman, Hrair Kirakossian, Sharat Singh,

Proceedings of the National Academy of Sciences

1994

327

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

Niels Vande Casteele, Reena Khanna, Barrett G. Levesque,

Gut

2014

283

Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method

Edwin F. Ullman, Hrair Kirakossian, Arthur C. Switchenko,

Clinical Chemistry

1996

253

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

Andrés Yarur, Anjali Jain, Daniel A. Sussman,

Gut

2015

234

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

Shui-Long Wang, Linda Ohrmund, Scott Hauenstein,

Journal of Immunological Methods

2012

203

Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

Johannan F. Brandse, Ron A. A. Mathôt, Desirée van der Kleij,

Clinical Gastroenterology and Hepatology

2015

194

Page 1